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Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of
vitamin E. Cyclosporine A (C5A) has been demonstrated to induce renal
microsomal lipid peroxidation in vitro. To examine whether CsA induces
lipid peroxidation in vivo, uninephrectomized rats were gavaged with
vehicle, CsA 12.5 or 25 mg/kg/day for four weeks. CsA-induced reduction
in GFR and RBF was associated with a dose-related increase in renal
cortical malondialdehyde (MDA) and conjugated diene, as well as a
similar increase in arterial MDA. The latter was apparent within two hours
of a single intraperitoneal injection of 25 mg/kg CsA and preceded the
acute fall in GFR. To address whether lipid peroxidation contributed to
CsA nephrotoxicity, rats were gavaged with vehicles, CsA 25 mg/kg/day or
CsA plus vitamin 11 25 mg/kg/day for eight weeks. Vitamine E, a lipid
radical scavenger, inhibited MDA raise and reduced CsA-induced renal
damage. Conversely, CsA administration to vitamin E and selenium
deficient rats was accompanied by a greater increase in arterial MDA and
fall in GFR. These novel findings, that CsA nephrotoxicity is associated
with lipid peroxidation and that a chain-breaking antioxidant ameliorates
whereas its deficiency exacerbates, indicate a rule for lipid peroxidation,
presumably free radical-mcdiated, in CsA toxicity.
Despite the established effectiveness of cyclosporine A (CsA) in
improving transplantation success rate and its potential therapeu-
tic role in a variety of immunological disorders including certain
types of glomerulonephritis, nephrotoxicity remains a major prob-
lem of CsA treatment [1]. Acutely, CsA may induce reversible
reduction in renal blood flow and GFR whereas its chronic
administration can lead to irreversible renal failure along with
prominent tubulointerstitial fibrosis [1, 2]. A number of mediators
and mechanisms have been proposed to account for CsA neph-
rotoxicity [2]. The bulk of the evidence points towards the
presence of excessive potent vasoconstrictors rather than the
absence of vasodilators [2, 3]. Endothelin is one such vasocon-
strictors whose level is elevated in CsA-treated transplant patients
[4]. A recent study employing selective endothelin receptor an-
tagonists, however, questions the role of endothelin in mediating
CsA-induced renal vasoconstriction [5]. On the other hand, there
appears a wider agreement on the role of thromboxane A2,
another potent vasoconstrictor and a metabolite of arachidonate
[6—8]. Consistent with a role for thromboxane A2 is the frequently
demonstrated salutary effect of fish oil supplementation during
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CsA therapy [9]. Omega-3 fatty acids, eicosapentaenoic and
docosahexaenoic acids, in fish oil by substituting the normal n-6
arachidonic acid, may, upon induction by CsA, generate less
potent and toxic metabolites: thromboxane A3 instead of A2 [10].
Reactive oxygen species (ROS) through a peroxidative process
may increase the availability of arachidonate metabolites and
enhance prostanoid production [11—13]. This is an intriguing
possibility since in vitro incubation of rat renal microsomes or
human liver microsomes with CsA induces dose-related lipid
peroxidation [14, 15]. The present study was undertaken to
examine whether CsA, like in in vitro, induces lipid peroxidation in
vivo and whether such lipid peroxidation plays a role in CsA-
induced nephrotoxicity.
As a composite of several studies, this paper provides evidence
to indicate that: (1.) CsA-nephrotoxicity in the rat is accompanied
by dose-related systemic and renal lipid peroxidation; (2.) tran-
sient spike in systemic lipid peroxidation after a single dose of
CsA precedes the fall in GFR; (3.) concurrent vitamin E therapy
with CsA suppresses CsA-induced lipid peroxidation and reduces
renal functional and structural damage; and finally (4.) CsA
administration to antioxidant deficient rats is accompanied by
evidence for greater lipid peroxidation and renal injury. Based on
these findings, we propose a role for lipid peroxidation, presum-
ably free radical-mediated, in CsA-induced renal toxicity in the rat
and further speculate that excess generation deleterious prostan-
oids is related to CsA-induced heightened arachidonate peroxi-
dation.
Methods
Effect of varying doses of CsA on renal function and lipid
peroxidation
Five days after subcostal right nephrectomy to simulate the
single renal allograft model, male Sprague-Dawley rats, matched
for body weight and serum creatinine, were assigned to three
groups, each consisting of six rats (Table 1). The initial body
weight of rats in this and subsequent studies were between 250 to
275 grams, unless indicated otherwise. The control rats were
gavaged daily with 1.5 ml/kg body weight of olive oil, the vehicle
in which CsA was diluted. The CsA groups received CsA 12.5 or
25 mg/kg/day in the same way. Throughout the four weeks, rats
were pair fed with standard laboratory rat chow (Purina) and their
food intake was monitored daily and body weight once a week.
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Table 1. Measurements in control rats, and in rats receiving CsA 12.5 and 25 mg/kg/day
Body weight
g Sr
mg/dl
Week 0
Hct
%
Week 4
Sprotjn
mg/dl
Week 4
Blood CsA
ng/ml
Week 4Week 0 Week 4
Control 253 4 342 12 0.50 0.03 0.49 0.005 5.9 0.2 —
CsA 12.5 mg/kg/day
CsA 25 mg/kg/day
254 3
257 6
338 9
321 8 0.48 0.030.50 0.03 0.47 0.003a0.47 0.004a 5.7 0.15.5 o.la 2948 3834424 260'
ap < 0.05 vs. control
bp < 0.05 vs. CsA 12.5 mg/kg/day
Renal hemodynamic measurements
Renal clearance studies were performed on the remaining
kidney at week 4 under euvolemic conditions on a heat-regulated
table as detailed in a previous study [161. On the day of clearance,
the daily dose of CsA was administered three hours before the
first clearance period to minimize variability in drug levels.
Following anesthesia, rats underwent catheterization, and fluid
loss during the study was replaced by an initial i.v. infusion of 6%
albumin (1% of body wt) for 30 minutes, followed by a mainte-
nance hourly infusion of 0.5 ml normal saline. Blood pressure and
temperature were continuously monitored. Hematocrit by the
microcapillary method and serum protein by the refractometry
method were determined at the start and end of clearance
periods. To determine glomerular filtration rate (GFR), a solu-
tion of 1 ml normal saline containing [125!] sodium iothalamate
(2 xCi/ml) was infused as a slow single bolus [17]. A 23-gauge
needle connected to a 1 ml syringe via PE tubing was left inserted
into the renal vein to obtain samples for 1251 iothalamate radio-
activity [18]. Filtration fraction (FF) was calculated from the renal
extraction of iothalamate [18]. GFR, renal blood flow (RBF),
calculated from GFR and FF, and renal vascular resistance
(RVR), calculated from mean arterial pressure and RBF, were
the mean of two consecutive clearance periods [16, 18]. Kidney
removed at the end was sectioned into two, rinsed in ice-cold
saline and the cortex was dissected out and stored immediately at
—84°C for malondialdehyde and conjugated diene measurements.
Plasma samples from femoral artery and renal veins and urine
samples were also frozen immediately for subsequent malondial-
dehyde determinations.
Measurement of lipid peroxidation
Evidence for lipid peroxidation in the renal cortical homoge-
nate was assessed by two different assay methods. Renal cortex
was homogenized in 100 m potassium chloride containing 3 mtvi
EDTA [18, 19]. Malondialdehyde in the supernatant was mea-
sured as thiobarbituric acid reactive substances (TBARS) by
colorimetric TBA reaction. Reaction was carried out in the
presence of EDTA (3 mM) and antioxidant butylated hydroxy-
toluene (BHT, 2.5 xl of 2% per ml) by the method of Ohakawa,
Oshishi and Yagi, and absorbance was determined spectrophoto-
metrically at 532 nm as described previously [19]. For conjugated
diene determination, supernatant was extracted in chloroform-
methanol mixture (2:1), dried in nitrogen, redissolved in cyclo-
hexane and read at 234 nm UV [20]. An extinction coefficient of
27,000 M' cm was used and values were corrected for protein
by Lowry method. TBARS were also measured in frozen femoral
arterial and renal vein plasma samples by the TBA reaction [21].
BHT (2.5 .d of 2%) was added to the reaction mixture to
minimize procedural lipid peroxidation [21]. In one study, lipid
peroxidation measured by previous TBA reaction method was
validated by a more specific method in which malondialdehyde-
TBA adduct was separated from interfering substances by high
pressure liquid chromatography (HPLC) as described in detail
previously [22]. Kidney homogenate supernatant samples, sub-
jected to methanol protein precipitation, were reacted with TBA
reagent as before and injected into HPLC system (Waters Inc.).
Malondialdehyde-TBA adduct in the sample was separated by the
C18 column and then quantitated spectrophotometrically at 532
nm.
Effect of acute administration of CsA on renal function and lipid
peroxidation
Rats were set up for renal clearance studies as above. Following
baseline measurements, CsA 25 mg/kg in olive oil or olive oil
alone were administered intraperitoneally through a small midline
abdominal incision. Clearances were conducted as above except
no renal vein catheters were placed. Samples were drawn at 1, 2,
4 and 6 hours after CsA instillation, and GFR and TBARS in
urine, femoral arterial and renal cortical homogenate samples
were determined. Plasma volume limited measurement of conju-
gated dienes to only before and six hours after CsA.
Effect of vitamin E on GsA-induced renal functional and
structural damage and lipid peroxidation
Five days after subcostal right nephrectomy, male Sprague-
Dawley rats, matched for body weight and serum creatinine were
assigned to three groups, each consisting of six rats. The control
rats were gavaged daily with 1.5 mllkg body weight of olive oil, the
vehicle in which CsA was diluted, and twice daily with 1.5 mI/kg of
20% Encapsin HPB (hydroxypropyl-B-cyclodextrin), the vehicle
in which alpha tocopherol acetate (vitamin E) was dissolved.
Encapsin is a cyclic oligosaccharide carrier molecule that in-
creases the solubility of lipophilic compound in aqueous solution;
this compound has been studied extensively and has been dem-
onstrated to have little deleterious effect on the kidney or other
organs [23]. The CsA group was gavaged daily with 25 mg/kg of
CsA in olive oil and twice daily with Encapsin, whereas the
vitamin E group was gavaged twice daily with vitamin E 25
mg/kg/day in Encapsin, in addition to CsA. Vitamin E potently
inhibits lipid peroxidation in biological membranes primarily by
scavenging lipid radicals [24]. Throughout this study, rats were
pair fed with standard laboratory rat chow (Purina) and their food
intake and body weight were monitored daily. Creatinine clear-
ance was measured at weeks 5 and 8 by standard 24-hour urine
collection in metabolic cages.
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Renal hemodynamic measurements were undertaken on these
rats at week 8 by the same clearance methods described above.
Malondialdehyde was measured in renal cortical homogenate by
TBA reaction with and without HPLC separation as described.
Conjugated diene could not be measured because we found that
vitamin E directly interfered with absorbance measurements at
234 nm UV.
Tubulointerstitial fibrosis, a frequent histological feature of
chronic CsA toxicity, was scored under light microscope. Fibrosis
consisting of subcapsular and striped interstitial fibrosis were
easily identified by the detailed previous descriptions [25] and
counted by scanning around the entire cortex of the kidney
section. A scoring system was employed as follows: 0 equals none,
ito 3 equals 1+, 4 to 6 equals 2+, 7 to 9 equals 3+, and more
than 9 equals 4+. A final mean score was obtained from each
kidney for statistical analysis.
Effect of vitamin E and selenium deficiency on GsA-induced renal
dysfunction and lipid peroxidation
Imposition of weanling rats to a diet deficient in vitamin E and
selenium for several weeks will lead to a chronic prooxidative
state, suggested by the heightened susceptibility to lipid peroxi-
dation [18]. Chronic vitamin E and selenium deficient model was
employed here to test indirectly whether CsA administration
induced oxidative stress. Renal injury associated with oxidative
stress is likely to be more pronounced in the antioxidant deficient
rats than sufficient controls [26]. Further, deficient rats are more
prone to lipid peroxidation and, therefore, if CsA induces lipid
peroxidation then deficient rats could be expected to sustain more
renal damage and lipid peroxidation following CsA administra-
tion. Rats weighing about 50 to 60 g were started on a vitamin E
and selenium deplete (TD84253) or replete (TD84254) diets
(Teklad, Madison, WI, USA) [18]. Creatinine clearance (Cr) was
determined at weeks 6 and 9, and CsA 25 mg/kg in olive oil was
gavaged daily from weeks 9 to 10. Ce,. was repeated at week 10,
following which rats were subjected to 1251 iothalamate clearance.
TBARS were measured in arterial plasma and renal cortical
tissue.
Materials
*
*
All chemicals were obtained from Sigma (St. Louis, MO, USA),
radiolabels from Amersham (Arlington Heights, IL, USA) and
special diets from Teklad.
Statistical methods
Results are presented as mean SEM. Data on multiple groups
were analyzed by ANOVA and corrected for multiple comparison
by Tukey's HSD (Systat, Inc., Evanston, IL, USA) and Student's
t-test was applied where appropriate. Significance was set at P <
0.05 level.
Results
Effect of vaFying doses of CsA on renal function and lipid
peroxidation parameters
Although pair fed, at the end of four weeks CsA-treated rats
had lower body weights than controls, and their hematocrits and
serum proteins were slightly lower (Table 1). Blood CsA levels
were elevated in a dose-related manner (Table 1), and in a similar
fashion, there was a reduction in GFR and RBF and an increase
in RVR (Fig. 1). These findings were accompanied by a dose-
dependent increase in lipid peroxidation parameters such as renal
cortical TBARS and conjugated dienes (Fig. 2). Administration of
CsA was also associated with increase in arterial and renal venous
plasma TBARS (Table 2). The increase in urinary excretion of
TBARS following CsA administration was significant when cor-
rected for GFR (Table 2).
Effect of acute administration of CsA on renal function and lipid
peroxidation parameters
Following intraperitoneal CsA, there was a time-related in-
crease in plasma TBARS, peaking at two hours (Fig. 3). The rise
in plasma TBARS was followed by a step-wise fall in GFR, with
nadir at four hours (Fig. 3) . Plasma conjugated diene (nmol/mg
protein) was also elevated following CsA (baseline vs. 6 hr:
control 0.08 0.01 vs. 0.07 0.01, P = NS; CsA 0.07 0.01 vs.
0.10 0.02, P < 0.05). Urinary TBARS excretion following CsA
was elevated significantly when corrected for GFR (Fig. 3).
TBARS in renal cortical homogenate was, however, not different
3
2
E
U-
CD
0
14
12
10•
8E
U- 4.
2.
0.
30
E 20
E
E 10
>
0
*
*
*
Control 12.5 25
GsA, mg/kg/day —
Fig. 1. Following 4 weeks of oral GsA 12.5 or 25 mg/kg/day or its vehicle,
olive oil (control), rats were subjected to renal clearance studies. * P < 0.05
vs. control.
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Fig. 2. Protocol as in Figure 1. Conjugated diene and malondialdehyde
(TBARS) were measured in renal cortical homogenate. * P < 0.05 vs.
control.
Table 2. TBARS measurements in control rats, and in rats receiving
CsA 12.5 and 25 mg/kg/day
Control 12.5 25
TBARS on week 4
Arterial Renal vein
nmol/ml
Urinary
nmol/ml/min GFR
Control
CsA 12.5 mg/kg/day
CsA 25 mg/kg/day
10.1 1.3 15.4 0.4
14.0 0.6* 15.4 0.6
17.0 0.T 18.3 0.6*
10.1 1.3
28.2 6.1
85.2 17.0
P < 0.05 vs. control
CSA or olive oil
. 14
>U) c
C . ::
2
Baseline 1 hr 2 hr 4 hr 6 hr
— Post-CSA or olive oil
Fig. 3. Following a single intraperitoneal administration of 25 mg/kg GsA(•) or its vehicle, olive oil (—011—), GFR (125Jiothalamate method) and
malondialdehyde (TBARS) in plasma and urine were measured at timed
intervals. *P < 0.05 vs. respective controls.
structural protection against GsA was accompanied by a marked
inhibition of CsA-induced increase in renal cortical malondialde-
hyde, measured by both standard TBA reaction as well as HPLC
separation methods (Fig. 5).
Effect of vitamin E and selenium deficiency on CsA-induced renal
dysfunction and lipid peroxidation parameters
Following a week's administration of CsA to both groups, there
was a marked fall in body weight in the vitamin E and selenium
deficient rats, but not in the sufficient controls (Table 4). Hemat-
ocrit was markedly lower in the CsA-treated deficient rats (Table
4). CsA induced greater renal dysfunction in lipid peroxidation-
prone deficient rats. During sequential GFR (Car) measurement,
CsA administration induced a greater fall in Cr in the deficient
than in the sufficient rats (Fig. 6). That CsA induced greater renal
dysfunction in lipid peroxidation-prone deficient rats was further
demonstrable by 1251 iothalamate measurement of GFR (Table
4). Also, CsA-treated deficient rats had higher arterial TBARS
(Fig. 6). Kidney cortical TBARS were also higher in the CsA-
treated deficient rats without reaching statistical significance
(Table 4).
in this study between the CsA-treated and untreated controls
(TBARS, 0.51 0.04 vs. 0.50 0.08 nmol/mg protein). Direct
addition of CsA into assay test tubes did not interfere with
TBARS or conjugated diene assays, indicating that CsA did not
directly interfere to account for the findings.
Effect of vitamin E on CsA -induced renal functional and
structural damage and lipid peroxidation parameters
CsA-induced reduction in body weight was not apparent in rats
receiving CsA plus chain-breaking antioxidant vitamin E (Table
3). Further, the CsA-induced persistent reduction in serial CC,.
measurements were not evident in the vitamin E-treated group
(Table 3). Decline in serum protein and hematocrit were marginal
and did not appear to progress with chronic administration of CsA
(Table 3). Confirming the serial Cr measurements, GFR, mea-
sured by the 125J iothalamate method, was better preserved in the
vitamin E group (Fig. 4). Similarly, RBF and RVR in the vitamin
E group were also better preserved than in the CsA alone group
(Fig. 4). Additionally, the CsA-induced increase in interstitial
fibrosis was effectively suppressed with co-administration vitamin
E (Fig. 4). Evidence that vitamin E afforded functional and
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Table 3. Measurements in the control rats, rats receiving CsA and rats receiving CsA as well as vitamin F
Week 0
Body weight
g
Week 5 Week 8
Cc.
mi/mm
HCT
%
Week 8
5p,o,e,n
mg/dl
Week 8Week 5 Week 8
Control 261 5 364 5 403 6 2.0 0.14 2.2 0.06 0.49 0.003 6.2 0.04
CsA 255 17 306 11/' 348 9 1.3 0.08a 1.12 0.07a 0.47 0.005" 5.9 0.04"
CsA + vit. F 257 7 355 6 396 6 2.3 0.20 2.1 0.14 0.46 0.003" 5.9 0.06
P C 0.05 vs. control and CsA
bp < 0.05 vs. control
+ vit. F
*
Control CsA CsA + E
two methods. Lipid peroxidation begins with free-radicals initi-
ated electron abstraction from the polyunsaturated membrane
lipids, leading to a series of chain reactions, including early diene
conjugation and final lipid peroxide and malondialdehyde forma-
tion [24]. The conjugated diene employed in this study reflects the
early stages of peroxidation and malondialdehyde, and the other
method measures the final decomposition products of peroxide.
The standard TBA method to measure malondialdehyde was
further validated by a more specific HPLC separation method
[24].
The present observations extend the previous findings from at
least two groups, and demonstrating the ability of CsA to induce
lipid peroxidation in vitro into the in vivo settings [14, 15].
Additionally, data in this study provide supportive evidence in vivo
for a role for ROS in CsA-induced nephrotoxicity. Furthermore,
data from the vitamin E-treatment suggest that the accompanying
lipid peroxidation may be important in the pathogenesis of
CsA-induced renal injury.
The role of accompanying lipid peroxidation in experimental
renal injury, in general, is not yet well understood [271. In a recent
in vitro study, we found that lipid peroxidation clearly preceded
oxidant-induced renal epithelial cell injury and lipid radical
scavengers, while effectively inhibiting lipid peroxidation pre-
vented cytolysis [28], The present finding of a renoprotective role
for chain-breaking antioxidant vitamin E in the rat model of CsA
*
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Fig. 5. Protocol as in Figure 4. Malondialdehyde in the renal cortical
homogenate was measured by the standard thiobarbituric acid (TBA)
reaction method (fl) as well as by a more specific HPLC separation
method (u). * P C 0.05 vs. respective control and CsA+F.ffL___
/
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*
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Fig. 4. Of the three groups of rats, control received vehicles, CsA received
CsA 25 mg/kg/day and CsA +E received, in addition to CsA 25 mg/kg/day,
vitamin F 25 mg/kg/day. Rats were subjected to renal clearance studies on
week 8. Renal tubulointerstitial fibrosis was scored under light micros-
copy. * P C 0.05 vs. control and CsA+E.
Discussion
We demonstrate for the first time that renal dysfunction
associated with chronic as well as acute administration of CsA in
the rat was accompanied by evidence for systemic and renal lipid
peroxidation. The lipid peroxidative process appeared important
in the pathogenesis of CsA nephrotoxicity since its inhibition by a
chain-breaking antioxidant, vitamin E, was associated with pres-
ervation of renal function and structure, and CsA administration
to vitamin E and selenium deficient rats was followed by greater
lipid peroxidation and renal dysfunction.
Since there is no one satisfactory method for measuring lipid
peroxidation, its presence was sought, as recommended [24], by
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Table 4. Measurements in vitamin E and selenium replete and deplete rats before and after a week of CsA
Body weight g
HCT
%
Sprote,,,
mg/dl
GFR
mi/mm
RBF
mi/mm
RVR
mm Hg mm/mi
Renal TBARS
nmol/mg
protein
Pre-CsA Post-CsA Post-CsA
Replete 353 9 351 10 0.47 0.009 6.2 0.15 1.6 0.28 15.6 2.5 8.7 1.8 1.5 0.1
Deplete 338 15 294 15 0.43 0.009 5.8 0.10 0.9 0.09" 7.6 0.8" 13.8 l.9' 2.0 0.3
a P < 0.05 vs. Pre-CsA
"p < 0.06 vs. replete
cp < 0.05 vs. replete
dp = 0.08
1.75
E 1.25
C,0
CSA
A I
nephrotoxicity is in line with the notion that membrane peroxida-
tion may contribute to renal injury process. Membrane, because of
its large surface area, is quite likely a frequent target for oxidative
attack, and peroxidation occurs with ease because of the unsatur-
ated nature of arachidonic acid. Peroxidation of the lipid and
attendant alterations in membrane fluidity can be an early and
critical event accounting for a number of self-amplifying second-
ary events [27]. Chronically, deleterious arachidonic acid metab-
olites, along with other mediators, may contribute and perpetuate
progressive renal injury [29]. As noted previously, several studies
demonstrate a role for arachidonate metabolite thromboxane in
CsA nephrotoxicity, and some have demonstrated a role for
transforming growth factor beta as well in renal fibrosis [6—8, 30].
Weight loss in CsA treated rats, despite equal food intake as
well as lack of any apparent illness, cannot easily be explained.
The high dose of CsA commonly employed in renal toxicity
studies might have been a factor, even though others have
reported weight loss associated with lower doses of CsA in the rat
[31]. Renal insufficiency in CsA rats, although modest, may be
another factor. Somatic weight loss has been previously reported
in antioxidant deficient rats [18], and indeed, a week's CsA
administration to antioxidant deficient rats but not sufficient rats
was associated with marked weight loss, implying a possible role
for oxidative stress. That co-administration of vitamin E limited
CsA-induced weight loss is yet another finding in our study
suggesting that oxidative stress might be an important factor
involved in weight loss.
Data herein also suggest that CsA-induced lipid peroxidation is
an acute transient phenomenon, temporally related to the dose of
CsA which is interestingly, in many ways, similar to the daily renal
hypoperfusion and hypofiltration reported with the regular daily
doses of CsA in renal transplant patients [32]. Arterial malondi-
aldehyde spiked at two hours and receded to baseline at six hours.
Malondialdehyde level, like in the blood, was also not high in
kidneys at six hours. Renal cortical malondialdehyde was, how-
ever, high in the chronic study. CsA accumulates in the kidney and
may incite chronic peroxidation, independent of the timing of the
last dose.
The finding in this study that lipid peroxidation is dose-related
raises the possibility that, if indeed lipid peroxidation occurs in
CsA-treated patients, even clinically employed lower doses can be
accompanied by low grade chronic lipid peroxidation. However, it
also remains possible that below a certain CsA dose level lipid
peroxidation may not occur. Stein et al examined for the presence
of lipid peroxidation in low dose CsA-treated rheumatoid arthritis
patients [33]. Serum creatinine, the only parameter monitoring
renal function, rose modestly, but well within the upper limit of
normal, to 0.81 0.04 mg/dl over a three month period of 2.5 to
3.5 mg/kg of CsA administration. Urinary malondialdehyde and
F2-isoprostanes measured in what appears to be spot samples of
urine were not elevated. This dose, relatively lower than what is
generally used in the transplant setting, is probably non-nephro-
toxic and the mild increase in serum creatinine could well be due
to alterations in tubular handling of creatinine, as previously
noted with uric acid [341. Moreover, based on the observation
herein that urinary excretion of malondiadehyde following a dose
of CsA is related to the timing of the dose, a spot sample of urine
if collected away from the last dose might provide no evidence for
lipid peroxidation. In contrast to this work, another study in
humans has reported increased urinary levels of lipoperoxides in
renal transplant patients receiving CsA [35]. Additional studies
are needed to verify the occurrence of CsA-related lipid peroxi-
dation in humans.
If CsA induces lipid peroxidation in humans, then chronic
*
B
Week 6 Week 9 Week 10
*
0.75
ci)
15.0
E
5.0
E 0.0
Fig. 6. Weanling rats were subjected to vitamin E and selenium deficient or
sufficient diets. A. Baseline Cr was measured at weeks 6 and 9. CsA 25
mg/kg/day was administered from weeks 9 to 10 and C. was repeated at
week 10. B. Arterial malondialdehyde (TBARS) was measured in these
rats at the end of CsA administration. * P < 0.05 vs. week 9 and j P < 0.05
vs. replete. Symbols in A are: (•) deplete; (El) replete.
Replete Deplete
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peroxidation of lipid may explain, in part, the high incidence of
accelerated atherosclerotic coronaiy artery disease, particularly
cardiac, reported in transplant patients [36]. In this regard, it is
worth noting again that co-administration of vitamin E in the rat
receiving CsA in this study was accompanied by inhibition of
excessive lipid peroxidation. CsA accumulates in the kidney
and so it may incite local peroxidation of cellular lipid with
several possible baneful effects, including direct cellular toxicity,
thromboxane-mediated ischemia and peroxidation-linked excess
extracellular matrix production [8, 28, 37]. It is also possible that
CsA, by lipid peroxidation, may stimulate the formation of newly
identified arachidonate metabolites, 8-epi-prostaglandin F2 a
(F2-isoprostanes), [12] which reportedly interact with thrombox-
ane A2 receptors and, when infused into the renal artery, induces
intense vasoconstriction [13], F2-isoprostanes may well be in-
volved in CsA nephrotoxicity. Although the beneficial effect of
vitamin E in this study is likely due to its ability to inhibit lipid
peroxidation, its other role of enhancing prostacyclin production
or reducing platelet aggregation cannot be excluded [38].
While newer indications are being defined for CsA, no effective
strategy is currently available to counter the nephrotoxic effects of
this potent and rather selective immunosuppressive agent that has
literally made transplantation of many organs a standard proce-
dure. Although a reduction in the CsA dose can, but not always
[39], minimize the toxicity, lower doses may not be therapeutically
desirable. Fish oil may have a therapeutic potential [9] which we
speculate may be because CsA induces peroxidation of arachi-
donic acid, the products of which are more potent and deleterious
to the kidney than that of omega-3 fatty acids of fish oil.
Our data that peroxidation of renal lipids may be an important
mechanism for CsA's toxic effect is also consistent with generally
recognized detrimental role for thromboxane [6—8]. The mecha-
nism leading to excessive thromboxane production following CsA
remains elusive. One reasonable speculation based on our data is
that increased renal production of thromboxane is linked to the
heightened lipid peroxidation, which in turn is a reflection of
enhanced oxygen free radical production. Whether CsA enhances
free radical production is yet to be demonstrated directly, how-
ever. Renal toxicity of a number of xenobiotics, adriamycin,
puromycin, paraquat, cisplatin and carbon tetrachloride, are
linked to the excessive generation of reactive oxygen products [12,
40—42]. CsA is extensively metabolized by liver microsomal
cytochrome P-450 enzyme systems, and a recent study reports that
administration of CsA induces a several-fold increase in renal
cytochrome P-450 [43]. We suspect, as in carbon tetrachloride
renal toxicity characterized by lipid peroxidation and renal fibro-
sis, that the cytochrome P-450 system may be a potential source
for the excess ROS generation [42]. Since superoxide radical
generation occurs during cytochrome P-450 activity [42], we
hypothesize that the CsA-induced increase in renal cytochrome
P-450 activity may result in excessive free radical formation (Fig.
7). Alternatively, like certain xenobiotics, CsA may "uncouple"
cytochrome P-450, diverting electron flow to molecular oxygen,
thereby generating excess free radicals [42].
In summary, this study provides evidence that CsA-induced
renal toxicity is associated with renal and systemic lipid peroxida-
tion and, based on the findings that a chain-breaking antioxidant
inhibited lipid peroxidation and limited CsA-related renal injury,
lipid peroxidation is considered to have a participatory role in the
injury process. It is postulated that cytochrome P-450 system may
02CsA
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Metabolites
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Fish oil
Vitamin E
Arachidonic metabolites &
peroxidation products
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Fig. 7. Oversimplified hypothesis linking oxygen free radicals, arachidonate
metabolites and peroxidation products to renal cytochrome P-450 system in
the pathogenesis of CsA-induced renal toxicity.
be a potential source for the excessive oxygen free radicals, and
that CsA-linked excess lipid peroxidation may contribute to
accelerated atheroslerosis which is prevalent in the transplant
population. In agreement with our in vivo finding is the recent
report that lipid peroxidation was increased in CsA-treated car-
diac transplant patients compared to coronary artery disease
patients [36], and vitamin E administration in CsA-treated cardiac
transplant patients tended to improve renal function [38].
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Appendix
Abbreviations used in this paper are: CsA, cyclosporine A; ROS,
reactive oxygen species; MDA, malondialdehyde; TBARS, thiobarbituric
acid reactive substances; GFR, glomerular filtration rate; RBF, renal
blood flow; and RVR, renal vascular resistance.
References
1. MYERS BD, SIBLEY R, NEWTON L, ToMIovIcH SJ, Bosi-nos C,
STINSON F, LUETSCFIER JA, WHITNEY DJ, KRANSNY D, COPLON NS:
The long-term course of cyclosporine-associated chronic nephropathy.
Kidney mt 33:590—600, 1988
2. KEOwN PA: The physiologic basis of experimental cyclosporine neph-
rotoxicity. Literature Scan: Transplantation. 6:1, 1991
3. BOBADILLA NA, TAPIA E, Fiw'co M, LOPEZ P, MENDOZA S, GARCIA-
TORRES R, ALVARADO JA, HERRERA-ACOSTA J: Role of nitric oxide in
934 Wang and Salahudeen: Lipid peroxidation in CsA toxicity
renal hemodynamic abnormalities of cyctosporine nephrotoxicity.
Kidney mt 46:773—779, 1994
4. GRIEFF M, LOERTSCHE R, SHOHAIB SA, STEWART DJ: Cyclosporine-
induced elevation in circulating endothelin-1 in patients with solid-
organ transplants. Transplantation 56:880—884, 1993
5. DAvis LS, HALEEN SJ, DOHERTY AM, CODY WL, KEISER JA: Effects
of selective endothelin antagonists on the hemodynamic response to
cyclosporine-A. JAm Soc Nephrol 4:1448—1454, 1994
6. PERico N, BENIGNINI A, ZOJA C, DEL\i'ti F, REMUzzI G: Functional
significnace of exaggerated renal thromboxane A2 synthesis induced
by cyclosporine-A. Am J Physiol 251 :F581—F587, 1986
7. COFFMAN TM, CARR DR, YARGER WE, KLOTMAN PE: Evidence that
renal prostaglandin and thromboxane production is stimulated in
chronic cyclosporine nephrotoxicity. Transplantation 43:282—285, 1987
8. PETRIC R, FREEMAN D, WALLACE C, MACDONALD J, STILLER C,
KEOWN P: Effect of cyclosporine on urinary prostanoid excretion,
renal blood flow, and glomerulotubular function. Transplantation
45:883—889, 1988
9. KELLY yE, MACKIE J, STROM TB: Cyclosporine-A plus fish oil:
Accentuate the positive, eliminate the negative. Transplant Proc
21:848—849, 1989
10. NEUMAYER H, HEINRICH M, SCHMISSAS M, HALLER H, WAGNER K,
LUFF FC: Amelioration of ischemic acute renal failure by dietary fish
oil administration in conscious dogs. JAm Soc Nephrol 3:1312—1320,
1992
11. BAUD L, NIvEz M, CHANSEL D, ARDAILLOU R: Stimulation by oxygen
radicals of prostaglandin production by rat renal glomeruli. Kidney mt
20:332—339, 1981
12. MORROW JD, AWAD JA, KATO T, TAKMIASHI K, BADAR KF, ROBERTS
L II, BURK RF: Formation of novel non-cyclooxygenase-derived
prostanoids (F2-Tsoprostanes) in carbon tetrachioride hepatotoxicity.
J C/in Invest 90:2502—2507, 1992
13. TAKAI-IASHI K, NAMMOUR RM, FUKUNAGA M, EBERT J, MORROW JD,
ROBERT L II, HOOVER RL, BADAR KF: Glomerular actions of a free
radical-generated novel prostaglandin, 8-epi-prostaglandin F2 a, in the
rat: Evidence for interaction with thromboxane A2 receptors. J Clin
Invest 90:136—141, 1992
14. INSELMANN G, HANNEMANN J, BAUMANN K: Cyclosporine A induced
lipid peroxidation and influence on glucose-6-phosphatase in rat
hepatic and renal microsomes. Res Common Chem Pathol Pharmacol
68:189—203, 1990
15. AHMED SS, STROBEL HW, NAPOLI KL, GREVEL J: Adenochrome
reaction implicates oxygen radicals in metabolism of cyclosporine A
and FK-506 in rat and human liver microsomes. J Pharmacol Exp Ther
265:1047—1054, 1993
16. SALAHUDEEN AK, CLARK EC, NATH KA: Hydrogen peroxide-induced
renal injury: A protective role for pyruvate in vitro and in vivo. J Clin
Invest 88:1886—1893, 1991
17. HALL JE, GUYTON AC, FARR BM: A single-injection method for
measuring glomerular filtration rate. Am J Physiol 232:F72—F76, 1977
18. NATH KA, SALAHUDEEN AK: Induction of renal growth and injury in
the intact rat kidney by dietary deficiency of antioxidants. J C/in Invest
86:1179—1192, 1990
19. OFIKAWA H, OsHIsHI N, YAGI K: Assay for lipid peroxidation in
animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351—
358, 1979
20. SLATER TF: Overview of methods used for detecting lipid peroxida-
tion. Met/i Enzymol 105:105, 1984
21. AUST SD: Lipid peroxidation, in CRC Handbook of Methods for
Oxygen Radical Research, edited by RA GREENWALD, Florida, CRC
Press, 1985, p 203—205
22. WONG SHY, KNOGHT JA, HOPFER SM, ZAHARIA 0, LEACH CM,
SUNDERMAN W: Lipid peroxides in plasma as measured by liquid
chromatographic separation of malondialdehyde-thiobarbituric acid
adduct. Clin Chem 33:214—220, 1987
23. HOSTETLER JS, HANSON LH, STEVEBS DA: Effect of cyclodextrin on
the pharmacology of antifungal oral azoles. Antimicrob Agents C/ic-
mother 364:477—480, 1992
24. HALLIWELL B, GUTrERIDGE JMC: Lipid peroxidation: A radical chain
reaction, in Free Radicals in Biology and Medicine, edited by B
HALLIWELL, JMC GUTrERIDGE, New York, Oxford University Press,
1989, pp 188—276
25. DEEPERINK H, LEY.SSAC PP, STARLINT H, STARKLINT H, KEMP E:
Long-term cyclosporin nephrotoxicity in the rat: Effects of renal
function and morphology. Nephrol Dial Transplant 3:317—326, 1988
26. NATH KA, PALLER MS: Dietary deficiency of antioxidants exacerbates
ischemic injury in the rat kidney. Kidney Int 38:1109—1117, 1990
27. WEINBERG JM: The cell biology of ischemic renal injury. Kidney mt
39:476—500, 1991
28. SALAFIUDEEN AK: Role of lipid peroxidation in H202-induced renal
epithelial (LLC-PK1) cell injury. Am J Physiol (in press)
29. NATH KA, SALAHUDEEN AK, SHAH SV: Cellular and biochemical
mechanisms in progressive renal disease, in Current Nephrology, edited
by HC GORNICK, New York, Mosby-Year Book, mc, 16 1993, pp
221—256
30. BORDER WA, OKUDA S, LANGUINO LR: Suppression of experimental
glomerulonephritis by antiserum against transforming growth factor
Bi. Nature 346:371—374, 1990
31. FERGUSON CJ, VON RUHLAND C, PARRY-JONES DJ: Low-dose cyclo-
sporine nephrotoxicity in the rat. Nephrol Dial Transplant 8:1259—
1263, 1993
32. PERIC0 N, RUGGENENTI P, GASPARI F, MosCoNI L, BENIGENI A,
AMUCHASTEGUI CS, GASPARINI F, REMUZZI G: Daily renal hypoper-
fusion induced by cyclosporine in patients with renal transplantation.
Transplantion 54:56—60, 1992
33. STEIN CM, LONGMIRE AW, MINTON TA, ROBERTS JL II, PINCUS T,
MORROW JD: Cyclosporine-induced alterations in renal function are
not associated with lipid peroxidation. Transplantation 58:386—388,
1994
34. UN HY, ROCHER LL, MCQUILLAN MA: Cyclosporine-induced hype-
rurecemia and gout. N EngI J Med 321:287—292, 1989
35. KNIGHT JA, CHEUNG AK, PIEPER RK, SERVILLA K: Incesed urinary
excretion of lipoperoxide levels in renal transplant patients. Ann Clin
Lab Sci 19:238—241, 1989
36. CHANCERELLE Y, LORGERIL M, VIRET R, CHIRON B, DUREAU G,
RENAUD S, KERGONORGONOU J: Increased lipid peroxidation in
cyclosporine-treated heart transplant recipients. Am J Cardiol 68:8 13—
816, 1991
37. HOUGLUM K, BRENNER DA, CHOJKIER M: d-a-Tocopherol inhibits
collagen a1 (I) gene expression in cultured human fibroblasts. Modu-
lation of constitutive collagen gene expression by lipid peroxidation.
J Clin Invest 87:2230—2235, 1991
38. DERAY G, BENHMIDA M, HOANG PU, MAKSUD P, AUPETIT B,
BAUMEALOU A, JACOBS C: Renal function and blood pressure in
patients receiving long-term, low-dose cyclosporine therapy for idio-
pathic autoimmune uveitis. Ann Intern Med 117:578—583, 1992
39. BUS JS, GIBSON JE: Paraquat: Model for oxidant-initiated toxicity.
Environ Health Perspect 55:37—44, 1984
40. MAYERS CE, MCGUIRE WP, LISS RH, IFRIM I, GROTIZINGER K,
YOUNG RC: Adriamycin: The role of lipid peroxidation in cardiac
toxicity and tumor response. Science 197:165—167, 1977
41. YOSHIMURA R, YOSHIMURA N, NAKATANI T, KUSUNOSE E, YAMAGU-
CHI T, OKA T, KISHIMOTO T: The effects of cyclosporine on renal
microsomal cytochrome P-450 systems. Clin Nephrol 40:339—345, 1993
42. FREEMAN BA, Cio JD: Biology of disease. Free radicals and tissue
injury. Lab Invest 47:412—426, 1982
43. LORGERIL M, BOISSONNAT P, SALEM P, MONJAUD I, MONNEZ C,
GUIDOLLET J, FERRERA R, DUREAU G, NINEYF J, RENAUD S: The
beneficial effect of dietary antioxidant supplementation on platelet
aggregation and cyclosporine treatment in heart transplant recipients.
Transplantation 58:193—194, 1994
